LAL-BR/2001: Study Treatment to Low Risk ALL

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: 6-Mercaptopurine; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Mercaptopurine; Methotrexate; Prednisone; Vincristine

Criteria

Inclusion Criteria:

• Diagnoses of low risk acute lymphoblastic leukemia in children no treated previously

Exclusion Criteria:

• Mature B-ALL (FABL3) or with cytogenetic ALL "Burkitt-like" alterations (t[8;14], t[2;8], t[8;22])

• Mixed forms of ALL

• Acute Leukemia no differentiate

• Patients with coronary disorders, valvular or hypertensive cardiopathy

• Patients with chronic liver disorders

• Chronic pulmonary disorders

• Renal insufficiency

• Neurologic disfunctions

• ECOG 3 and 4

• No signed consent form